At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable ...
ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable residual disease (MRD)-negative responses in the first four patients with relapsed ...
Results of a small study presented at the 66th American Society of Hematology Annual Meeting & Exposition suggest combining the bispecific elranatamab with the proteasome inhibitor carfilzomib can ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback